Entry level $29.15, if market regains some strength
target price $35.50 = Stop loss $27.50
Golden cross is a very reliable buy signal and alerts new investors.
Stock has also been highlighted by ZAckz as atop value to stock to buy.
Average analysts price target $ 31 | Overweight
Short interest 3.4%
Company profile
Bausch Health Cos., Inc. engages in the...
Based on current set-up and price resistance, I'm looking for BHC to test its 20day EMA before heading northward
Trade:
ITM 27.50 Ps
If crosses 10 d EMA
Target 20 d EMA ~26.40
Elliott Wave View in Bausch Health (BHC) suggests the rally from June 4 low (20.28) unfolded as a 5 waves impulse Elliott Wave structure. Up from 20.28, wave (1) ended at 21.9 and wave (2) pullback ended at 20.8. The stock then resumes the rally higher in wave (3) towards 25.85, and wave (4) pullback ended at 24.61. Finally, the stock ended wave (5) of ((1)) at...
using EWT. EWT is great with counting the waves. To benefit from an accurate count, one must know how to use the wave count. I have used the EW as a tool to help me with my swing trading. I endeavor to buy calls at the end of wave 2 &4 (or beginning of wave 1,3&5) and exit my positions (take profits at the end of wave 1,3,&5 (or beginning of wave 2&4). I have been...
Diagonal. This Chart shows the three possible targets starting from the Fib 0.618 extension of wave 1-3, to the Top Rail of the Leading Diagonal , to the Target of the Cup n Handle. Please DYODD. I am holding Oct 19 $24 Calls which are currently over 100% up.
Good afternoon Traders,
BHC short-term Elliott wave analysis suggests that the pullback to $20.28 low ended black wave ((2)) pullback.
Up from there, it is in a possible 5 waves Elliott Wave structure higher. The first leg higher in black wave ((i)) ended at 09/13 peak (24.13). The internal structure of that move unfolded as a 5 wave impulse.
It ended blue...
Strong buy after MA 200 has come with insane violence. After a pull back of few days we have seen the start of a new uptrend. First TP is around 26,7 dollars where the gap down has left its trail.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
BHC
